View PDF Edition - U.S. Pharmacist

More documents

Recommendations

Info

Day 1Day 2 Day 3 Day 4 Day 5TAKE Z-PAK ® FOR 5 DAYS 1 OR...(azithromycin) 250 mgTAKE AZITHROMYCIN TO1 DAY. 1 DOSE.2Please see accompanying Zmax brief summary.Zmax is indicated for mild to moderate acute bacterialsinusitis in adults due to Haemophilus influenzae, Moraxellacatarrhalis, or Streptococcus pneumoniae and is also indicatedfor community-acquired pneumonia due to Chlamydophilapneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae,oror Streptococcus pneumoniae in adult and pediatric patientsaged 6 months and over, deemed appropriate for oral therapy.Zmax and Zithromax are contraindicated in patients withknown hypersensitivity to azithromycin, erythromycin, or anymacrolide or ketolide antibiotic. If an allergic reaction occurs,appropriate therapy should be instituted. Physicians should beaware that reappearance of the allergic symptoms may occurwhen symptomatic therapy is discontinued.There have been rare reports of serious allergic reactions includingangioedema, anaphylaxis, Stevens Johnson syndrome, and toxicepidermal necrolysis in patients on other formulations ofazithromycin therapy. Rarely, fatalities have been reported.Clostridium difficile associated diarrhea (CDAD) has beenreported with use of nearly all antibacterial agents, includingazithromycin, and may range in severity from mild diarrheato fatal colitis. CDAD must be considered in all patients whopresent with diarrhea following antibiotic use. Carefulmedical history is necessary since CDAD has been reported tooccur over two months after the administration ofantibacterial agents. If CDAD is suspected or confirmed,ongoing antibiotic use not directed against C. difficile may needto be discontinued, and appropriate management and treatmentof C. difficile should be instituted as clinically indicated.As with all macrolides, including Zmax, exacerbations ofmyasthenia gravis have been reported.
Zmax: 1 product — indicated for bothadult and pediatric patients 2PediatricpatientsAdultpatientsA higher incidence of gastrointestinal adverse events (8 of 19subjects) was observed when Zmax was administered to alimited number of subjects with GFR
Page 5 and 6:
USE IN SPECIFIC POPULATIONSPregnanc
Page 7 and 8:
U.S. PharmacistWhat’s NewsEditori
Page 9 and 10:
Q. Which Global Generic Company’s
Page 11 and 12:
If key productsare missing from you
Page 13 and 14:
1,500+ WaysWe Meet Your Needs
Page 15 and 16:
✁PATIENT INFORMATIONCombating Fat
Page 17 and 18:
Consult Your Pharmacistsleep, wheth
Page 19 and 20:
PATIENT TEACHING AIDBipolarDisorder
Page 21 and 22:
Our most important ingredient is in
Page 23 and 24:
IN THE TREATMENT OF MRSA BACTEREMIA
Page 25 and 26:
SCHIZOPHRENIA: A REVIEW OF TREATMEN
Page 28 and 29:
SCHIZOPHRENIA: A REVIEW OF TREATMEN
Page 30 and 31:
HEALTH SYSTEMS EDITION© JUPITERIMA
Page 32 and 33:
FENTANYL TRANSDERMAL SYSTEMBRIEF SU
Page 34 and 35:
other opioids, or to subtract the f
Page 36:
TRAUMATIC BRAIN INJURYHEALTH SYSTEM
Page 40 and 41:
HEALTH SYSTEMS EDITIONNewly Approve
Page 42 and 43: HEALTH SYSTEMS EDITIONMTOR INHIBITO
Page 48 and 49: HEALTH SYSTEMS EDITIONIn-Service Pr
Page 50 and 51: NUTRITION AND CLINICAL DEPRESSIONHE
Page 52 and 53: NUTRITION AND CLINICAL DEPRESSIONHE
Page 54: NUTRITION AND CLINICAL DEPRESSIONHE
Page 57 and 58: PROGRESSIVE SUPRANUCLEAR PALSYlabil
Page 60 and 61: FDA Fast FactsNew LeukemiaTreatment
Page 62: So Many Options,So Little Differenc
Page 66: WHAT IS THE APPROPRIATE ANTIDEPRESS
Page 75 and 76: WHAT IS THE APPROPRIATE ANTIDEPRESS
Page 77 and 78: OPIOID MAINTENANCE TREATMENTTable 1
Page 79 and 80: KAPIDEX is the first and only PPI w
Page 81 and 82: Nursing Mothers
Page 83 and 84: Table 3Potential Drug Interactions
Page 85 and 86: Providing Affordable andInnovative
Page 87 and 88: GREENSTONELLCWatch Our Product Line
Page 89 and 90: Contemporary Compoundinglevel in le
Page 91: PHARMACOLOGIC MANAGEMENT OF ALCOHOL
Page 95 and 96: PHARMACOLOGIC MANAGEMENT OF ALCOHOL
Page 97 and 98: CRIMINALIZATION OF MEDICATION ERROR
Page 99 and 100: &are excited to launch:www.PharmQD.
Page 101 and 102: Table 1Early Barriers PreventingUti
Page 103 and 104: EMERGENCY CONTRACEPTION: AN UPDATEo
Page 105 and 106: EMERGENCY CONTRACEPTION: AN UPDATEs
Page 107 and 108: EMERGENCY CONTRACEPTION: AN UPDATE1
Page 109 and 110: Examination Answer SheetCredits: 2.
Page 111 and 112: U.S. Pharmacist ClassifiedsCAREER O
Page 113 and 114: ONGLYZA (saxagliptin) tabletsBrief
show all

View PDF Edition - U.S. Pharmacist

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?